These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15990007)

  • 1. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT).
    Vu-Nishino H; Tavassoli FA; Ahrens WA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1040-7. PubMed ID: 15990007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy.
    Liu GF; Yang Q; Haffty BG; Moran MS
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1304-8. PubMed ID: 19386432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy.
    Vo T; Xing Y; Meric-Bernstam F; Mirza N; Vlastos G; Symmans WF; Perkins GH; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Akins JS; Hunt KK
    Am J Surg; 2007 Oct; 194(4):527-31. PubMed ID: 17826073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma.
    Thurman SA; Schnitt SJ; Connolly JL; Gelman R; Silver B; Harris JR; Recht A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):152-9. PubMed ID: 15093911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
    Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
    Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer.
    Benitez PR; Keisch ME; Vicini F; Stolier A; Scroggins T; Walker A; White J; Hedberg P; Hebert M; Arthur D; Zannis V; Quiet C; Streeter O; Silverstein M
    Am J Surg; 2007 Oct; 194(4):456-62. PubMed ID: 17826055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
    Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
    Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
    Jolly S; Kestin LL; Goldstein NS; Vicini FA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up.
    Antonucci JV; Wallace M; Goldstein NS; Kestin L; Chen P; Benitez P; Dekhne N; Martinez A; Vicini F
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):447-52. PubMed ID: 19058921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma.
    van der Sangen MJ; van de Poll-Franse LV; Roumen RM; Rutten HJ; Coebergh JW; Vreugdenhil G; Voogd AC
    Eur J Surg Oncol; 2006 Feb; 32(1):34-8. PubMed ID: 16305821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?
    Chagpar AB; McMasters KM; Sahoo S; Edwards MJ
    Surgery; 2009 Oct; 146(4):561-7; discussion 567-8. PubMed ID: 19789013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
    Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
    Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
    Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
    J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of external boost volume in breast-conserving therapy on local control with long-term follow-up.
    Jobsen JJ; van der Palen J; Ong F
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):115-22. PubMed ID: 18234450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.